MoFo News Item

MoFo Advises Sequlite on Sale to Fapon Biotech

17 Dec 2021

Morrison & Foerster advised Sequlite Genomics, a company that focuses on developing Next-Generation Sequencing (NGS) technology, in connection with its sale to Fapon Biotech, a biotechnology services company based in China that develops, manufactures, and sells products that provide global diagnostic companies with high-performance in vitro diagnostic reagent raw materials, as well as reagent solutions and innovative open instrument platforms. Sequlite specializes in the research and development of NGS instruments and reagents.

The MoFo team advising Sequlite was led by San Diego corporate partner Jim Krenn, together with San Diego corporate associates Andrew Dixon, Pat Boyle, Carey Hughes and Brennen Brodersen. The wider team included San Francisco tax partner Maureen Linch and tax associates Lauren Keller and Jessica Stern, San Francisco executive compensation partner Amanda Hines Gold and associate John O’Neill, Palo Alto labor of counsel Lloyd Aubry, Boston TTG partner Matt Karlyn and associate Mai Zymaris, Hong Kong TTG partner Chuan Sun, Hong Kong corporate senior of counsel Stephen Birkett, Beijing corporate associate Richard Ji, Shanghai corporate associate Tian Zhou, Washington D.C. partner Aki Bayz, and many others.

Close
Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.